

Theodore R Levin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2798082/publications.pdf>

Version: 2024-02-01

113
papers

21,920
citations

28274

55
h-index

23533

111
g-index

118
all docs

118
docs citations

118
times ranked

15519
citing authors

#	ARTICLE	IF	CITATIONS
1	Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 145-152.	4.4	21
2	Risk stratification for colorectal cancer in individuals with subtypes of serrated polyps. <i>Gut</i> , 2022, 71, 2022-2029.	12.1	14
3	Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS208-TPS208.	1.6	5
4	Association between Improved Colorectal Screening and Racial Disparities. <i>New England Journal of Medicine</i> , 2022, 386, 796-798.	27.0	28
5	Current and future colorectal cancer screening strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 521-531.	17.8	102
6	Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population. <i>Gastroenterology</i> , 2022, 163, 723-731.e6.	1.3	18
7	Disparities in Preventable Mortality from Colorectal Cancer: Are They the Result of Structural Racism?. <i>Gastroenterology</i> , 2021, 160, 1022-1025.	1.3	9
8	Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1793-1795.	4.4	0
9	Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. <i>Gastroenterology</i> , 2020, 158, 884-894.e5.	1.3	85
10	Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2020, 159, 1695-1704.e1.	1.3	18
11	Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2734-2741.e6.	4.4	14
12	What Is Organized Screening and What Is Its Value?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 393-411.	1.4	15
13	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 283-298.	329.8	75
14	Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. <i>Gastroenterology</i> , 2020, 159, 502-511.e2.	1.3	27
15	Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test. <i>Population Health Management</i> , 2019, 22, 83-89.	1.7	4
16	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. <i>Annals of Internal Medicine</i> , 2019, 170, 736.	3.9	2
17	Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00010.	2.5	27
18	Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings. <i>JAMA Internal Medicine</i> , 2019, 179, 153.	5.1	57

#	ARTICLE	IF	CITATIONS
19	Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. <i>Gastroenterology</i> , 2019, 156, 63-74.e6.	1.3	78
20	Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e25-e30.	2.2	24
21	Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. <i>Gut</i> , 2018, 67, 291-298.	12.1	264
22	Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcare setting. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 755-765.e1.	1.0	28
23	Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e186.	2.5	6
24	In Screening for Colorectal Cancer, Is the FIT Right for the Right Side of the Colon?. <i>Annals of Internal Medicine</i> , 2018, 169, 650.	3.9	7
25	Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. <i>Gastroenterology</i> , 2018, 155, 1383-1391.e5.	1.3	329
26	Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. <i>Annals of Internal Medicine</i> , 2018, 169, 439-447.	3.9	47
27	Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 509.	2.6	15
28	Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. <i>American Journal of Preventive Medicine</i> , 2017, 53, 335-344.	3.0	13
29	Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1631.	7.4	198
30	Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2017, 153, 307-323.	1.3	512
31	Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2017, 112, 1016-1030.	0.4	483
32	In simulation modelling, there are multiple ways to effectively screen for colorectal cancer. <i>Evidence-Based Medicine</i> , 2017, 22, 59-59.	0.6	0
33	Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. <i>Digestive Diseases and Sciences</i> , 2017, 62, 678-688.	2.3	12
34	Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests. <i>Annals of Internal Medicine</i> , 2017, 167, 565.	3.9	91
35	A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. <i>American Journal of Gastroenterology</i> , 2017, 112, 1728-1735.	0.4	56
36	Colorectal Cancer Screening: Money Isn't Everything . . . But It Helps!. <i>Gastroenterology</i> , 2017, 153, 1181-1183.	1.3	4

#	ARTICLE	IF	CITATIONS
37	The Best Laid Plans: Adaptation is an Essential Part of Going From Efficacy Research to Program Implementation. <i>Gastroenterology</i> , 2017, 152, 693-694.	1.3	1
38	Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 18-33.	1.0	145
39	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2017, 112, 37-53.	0.4	56
40	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2017, 152, 1217-1237.e3.	1.3	268
41	Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 2-21.e3.	1.0	55
42	Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 85-94.	2.5	168
43	Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. <i>Journal of General Internal Medicine</i> , 2016, 31, 1323-1330.	2.6	50
44	Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 672-681.	1.5	24
45	Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening. <i>Annals of Internal Medicine</i> , 2016, 164, 456.	3.9	186
46	Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 489-498.e10.	1.0	20
47	Ten-year incidence of colorectal cancer following a negative screening sigmoidoscopy: an update from the Colorectal Cancer Prevention (CoCaP) programme. <i>Gut</i> , 2016, 65, 271-277.	12.1	3
48	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 344-350.	2.5	106
49	Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2016, 111, 337-346.	0.4	59
50	Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2016, 150, 758-768.e11.	1.3	151
51	Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 552-554.	1.0	9
52	Colorectal cancer deaths attributable to nonuse of screening in the United States. <i>Annals of Epidemiology</i> , 2015, 25, 208-213.e1.	1.9	102
53	Development and validation of an algorithm for classifying colonoscopy indication. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 575-582.e4.	1.0	26
54	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2349.	7.4	72

#	ARTICLE	IF	CITATIONS
55	Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. <i>BMC Cancer</i> , 2015, 15, 123.	2.6	17
56	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. <i>Cancer</i> , 2015, 121, 2281-2285.	4.1	180
57	CDC Grand Rounds: the future of cancer screening. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 324-7.	15.1	5
58	Adenoma Detection Rate and Risk of Colorectal Cancer and Death. <i>New England Journal of Medicine</i> , 2014, 370, 1298-1306.	27.0	1,653
59	Multitarget Stool DNA Testing for Colorectal-Cancer Screening. <i>New England Journal of Medicine</i> , 2014, 370, 1287-1297.	27.0	1,352
60	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1147-1158.	2.5	64
61	Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 543-562.	1.0	106
62	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1528-1545.	0.4	119
63	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1159-1179.	0.4	363
64	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2014, 147, 502-526.	1.3	397
65	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2014, 147, 903-924.	1.3	322
66	Accuracy of Fecal Immunochemical Tests for Colorectal Cancer. <i>Annals of Internal Medicine</i> , 2014, 160, 171-181.	3.9	528
67	The Road Ahead: What if Gastroenterologists Were Accountable for Preventing Colorectal Cancer?. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 204-207.	4.4	18
68	Health Benefits and Cost-effectiveness of a Hybrid Screening Strategy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1158-1166.	4.4	40
69	Variation of Adenoma Prevalence by Age, Sex, Race, and Colon Location in a Large Population: Implications for Screening and Quality Programs. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 172-180.	4.4	197
70	Effectiveness and Reach of the FLU-FIT Program in an Integrated Health Care System: A Multisite Randomized Trial. <i>American Journal of Public Health</i> , 2013, 103, 1128-1133.	2.7	25
71	Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults. <i>Annals of Internal Medicine</i> , 2013, 158, 312.	3.9	142
72	The Importance of Choosing Colorectal Cancer Screening Tests. <i>Archives of Internal Medicine</i> , 2012, 172, 582.	3.8	6

#	ARTICLE	IF	CITATIONS
73	Editorial: Taking FIT to the People: Out of the Office and Into the Mail. <i>American Journal of Gastroenterology</i> , 2012, 107, 108-110.	0.4	4
74	Diagnosis, Comorbidities, and Management of Irritable Bowel Syndrome in Patients in a Large Health Maintenance Organization. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 37-45.	4.4	72
75	Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010. <i>Gastroenterology</i> , 2012, 143, 382-389.	1.3	273
76	Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2012, 143, 844-857.	1.3	1,717
77	Automated phone and mail population outreach to promote colorectal cancer screening. <i>American Journal of Managed Care</i> , 2012, 18, 370-8.	1.1	26
78	Optimizing Colorectal Cancer Screening by Getting FIT Right. <i>Gastroenterology</i> , 2011, 141, 1551-1555.	1.3	17
79	Organized Colorectal Cancer Screening in Integrated Health Care Systems. <i>Epidemiologic Reviews</i> , 2011, 33, 101-110.	3.5	163
80	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 130-160.	329.8	1,491
81	Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. <i>Drug Safety</i> , 2008, 31, 325-334.	3.2	31
82	Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. <i>Gastroenterology</i> , 2008, 134, 1570-1595.	1.3	2,002
83	Dietary Antioxidants, Fruits, and Vegetables and the Risk of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 1614-1623.	0.4	80
84	Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia. <i>Annals of Internal Medicine</i> , 2008, 149, 441.	3.9	244
85	Implications of New Colorectal Cancer Screening Technologies for Primary Care Practice. <i>Medical Care</i> , 2008, 46, S138-S146.	2.4	12
86	Dealing With Uncertainty: Surveillance Colonoscopy After Polypectomy. <i>American Journal of Gastroenterology</i> , 2007, 102, 1745-1747.	0.4	9
87	Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. <i>Carcinogenesis</i> , 2007, 28, 1672-1679.	2.8	93
88	Change in Body Size and the Risk of Colorectal Adenomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 526-531.	2.5	77
89	Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1462-1470.	6.3	346
90	Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 757-766.	1.0	258

#	ARTICLE	IF	CITATIONS
91	Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. <i>International Journal of Cancer</i> , 2007, 120, 656-663.	5.1	177
92	Interactions Between CYP2C9 and UGT1A6 Polymorphisms and Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer Prevention. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 894-901.	4.4	46
93	Complications of Colonoscopy in an Integrated Health Care Delivery System. <i>Annals of Internal Medicine</i> , 2006, 145, 880.	3.9	489
94	PPAR β and Colon and Rectal Cancer: Associations with Specific Tumor Mutations, Aspirin, Ibuprofen and Insulin-Related Genes (United States). <i>Cancer Causes and Control</i> , 2006, 17, 239-249.	1.8	44
95	Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia. <i>Clinical Chemistry</i> , 2006, 52, 2299-2302.	3.2	20
96	Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. <i>Cancer Research</i> , 2005, 65, 6063-6069.	0.9	701
97	Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. <i>Gut</i> , 2005, 54, 807-813.	12.1	51
98	Associations between apoE genotype and colon and rectal cancer. <i>Carcinogenesis</i> , 2005, 26, 1422-1429.	2.8	61
99	Screening in liver disease: Report of an AASLD clinical workshop. <i>Hepatology</i> , 2004, 39, 1204-1212.	7.3	57
100	Long-Term Drug Treatment of GERD. <i>Disease Management and Health Outcomes</i> , 2004, 12, 399-407.	0.4	1
101	Colorectal cancer screening and surveillance: Clinical guidelines and rationale? Update based on new evidence. <i>Gastroenterology</i> , 2003, 124, 544-560.	1.3	2,016
102	What Does Sigmoidoscopy Really Miss?. <i>American Journal of Gastroenterology</i> , 2003, 98, 2326-2327.	0.4	2
103	Re: Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2003, 95, 830-831.	6.3	7
104	Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2002, 97, 1296-1308.	0.4	961
105	Complications of screening flexible sigmoidoscopy. <i>Gastroenterology</i> , 2002, 123, 1786-1792.	1.3	103
106	Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted?. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 1015-1029.	2.2	9
107	Flexible Sigmoidoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 23-40.	1.4	15
108	Quality of Life Measurement Clarifies The Cost-Effectiveness of Helicobacter Pylori Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. <i>American Journal of Gastroenterology</i> , 2001, 96, 338-347.	0.4	48

#	ARTICLE	IF	CITATIONS
109	Cimetidine Use and Risk of Breast, Prostate, and Other Cancers. , 2000, 9, 149-155.		17
110	Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization. American Journal of Gastroenterology, 2000, 95, 788-792.	0.4	104
111	Predicting Advanced Proximal Colonic Neoplasia With Screening Sigmoidoscopy. JAMA - Journal of the American Medical Association, 1999, 281, 1611.	7.4	163
112	Omeprazole Improves Peak Expiratory Flow Rate and Quality of Life in Asthmatics With Gastroesophageal Reflux. American Journal of Gastroenterology, 1998, 93, 1060-1063.	0.4	84
113	Costs of Acid-Related Disorders to a Health Maintenance Organization. American Journal of Medicine, 1997, 103, 520-528.	1.5	102